Published in Arch Neurol on October 01, 2002
Effects of Coenzyme Q10 (CoQ) in Parkinson Disease (QE3) | NCT00740714
Coenzyme Q10 in Huntington's Disease (HD) (2CARE) | NCT00608881
Phase III Trial of Coenzyme Q10 in Mitochondrial Disease | NCT00432744
Effects of Coenzyme Q10 on Charcot-Marie-Tooth Disease | NCT00541164
Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs (2008) 2.62
A novel neuroprotective therapy for Parkinson's disease using a viral noncoding RNA that protects mitochondrial complex I activity. J Exp Med (2011) 2.10
The role of oxidative stress in Parkinson's disease. J Parkinsons Dis (2013) 1.86
Neurodegeneration and neuroprotection in Parkinson disease. NeuroRx (2004) 1.77
Prospective study of statin use and risk of Parkinson disease. Arch Neurol (2012) 1.76
Longitudinal follow-up of SWEDD subjects in the PRECEPT Study. Neurology (2014) 1.70
Aging in individuals with the FMR1 mutation. Am J Ment Retard (2004) 1.68
Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment. J Bioenerg Biomembr (2004) 1.53
Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol (2005) 1.52
Mitochondrial approaches for neuroprotection. Ann N Y Acad Sci (2008) 1.48
Adjusting O'Brien's test to control type I error for the generalized nonparametric Behrens-Fisher problem. Biometrics (2005) 1.47
Coenzyme Q10 levels are low and associated with increased mortality in post-cardiac arrest patients. Resuscitation (2012) 1.47
Nrf2-mediated protection against 6-hydroxydopamine. Brain Res (2007) 1.42
Human coenzyme Q10 deficiency. Neurochem Res (2006) 1.34
α-Synuclein genetic variants predict faster motor symptom progression in idiopathic Parkinson disease. PLoS One (2012) 1.33
Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures. Arch Neurol (2012) 1.32
Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann Neurol (2009) 1.31
Update on the pathogenesis of Parkinson's disease. J Neurol (2008) 1.27
Treatment of CoQ(10) deficient fibroblasts with ubiquinone, CoQ analogs, and vitamin C: time- and compound-dependent effects. PLoS One (2010) 1.26
Autophagy as an essential cellular antioxidant pathway in neurodegenerative disease. Redox Biol (2013) 1.24
Redox proteomics in selected neurodegenerative disorders: from its infancy to future applications. Antioxid Redox Signal (2012) 1.24
Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases. J Neurochem (2009) 1.22
Current approaches to the treatment of Parkinson's disease. Neuropsychiatr Dis Treat (2008) 1.19
The DNA polymerase gamma Y955C disease variant associated with PEO and parkinsonism mediates the incorporation and translesion synthesis opposite 7,8-dihydro-8-oxo-2'-deoxyguanosine. Hum Mol Genet (2007) 1.19
The Role of Oxidative Stress in Neurodegenerative Diseases. Exp Neurobiol (2015) 1.16
Characterization of intracellular elevation of glutathione (GSH) with glutathione monoethyl ester and GSH in brain and neuronal cultures: relevance to Parkinson's disease. Exp Neurol (2006) 1.14
Complementation of Saccharomyces cerevisiae coq7 mutants by mitochondrial targeting of the Escherichia coli UbiF polypeptide: two functions of yeast Coq7 polypeptide in coenzyme Q biosynthesis. J Biol Chem (2006) 1.10
Mitochondrial contribution to Parkinson's disease pathogenesis. Parkinsons Dis (2011) 1.10
Striatal dysfunctions associated with mitochondrial DNA damage in dopaminergic neurons in a mouse model of Parkinson's disease. J Neurosci (2011) 1.09
Targets for neuroprotection in Parkinson's disease. Biochim Biophys Acta (2008) 1.08
Neuroprotective effects of compounds with antioxidant and anti-inflammatory properties in a Drosophila model of Parkinson's disease. BMC Neurosci (2009) 1.08
Genetic findings in Parkinson's disease and translation into treatment: a leading role for mitochondria? Genes Brain Behav (2007) 1.07
Determinants of the timing of symptomatic treatment in early Parkinson disease: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) Experience. Arch Neurol (2009) 1.06
The natural history of Parkinson's disease. J Neurol (2006) 1.05
Mitochondria-targeted antioxidants for treatment of Parkinson's disease: preclinical and clinical outcomes. Biochim Biophys Acta (2013) 1.04
Coenzyme Q10 effects in neurodegenerative disease. Neuropsychiatr Dis Treat (2009) 1.01
Paraquat induces oxidative stress, neuronal loss in substantia nigra region and parkinsonism in adult rats: neuroprotection and amelioration of symptoms by water-soluble formulation of coenzyme Q10. BMC Neurosci (2009) 1.00
Endpoints and analyses to discern disease-modifying drug effects in early Parkinson's disease. AAPS J (2009) 0.99
Using global statistical tests in long-term Parkinson's disease clinical trials. Mov Disord (2009) 0.98
Evaluation of coenzyme Q as an antioxidant strategy for Alzheimer's disease. J Alzheimers Dis (2008) 0.98
Medical management of Parkinson's disease. P T (2008) 0.98
The promise of neuroprotective agents in Parkinson's disease. Front Neurol (2011) 0.96
Coenzyme Q10: is there a clinical role and a case for measurement? Clin Biochem Rev (2008) 0.95
Effects of acute and 14-day coenzyme Q10 supplementation on exercise performance in both trained and untrained individuals. J Int Soc Sports Nutr (2008) 0.94
Bioenergetic medicine. Br J Pharmacol (2014) 0.93
Mitochondrial medicine for neurodegenerative diseases. Int J Biochem Cell Biol (2010) 0.93
Improvement of neuropathology and transcriptional deficits in CAG 140 knock-in mice supports a beneficial effect of dietary curcumin in Huntington's disease. Mol Neurodegener (2012) 0.93
Pathogenesis-targeted, disease-modifying therapies in Parkinson disease. Neurotherapeutics (2014) 0.92
Role and treatment of mitochondrial DNA-related mitochondrial dysfunction in sporadic neurodegenerative diseases. Curr Pharm Des (2011) 0.90
Mitochondrial mechanism of neuroprotection by CART. Eur J Neurosci (2007) 0.90
Combined R-alpha-lipoic acid and acetyl-L-carnitine exerts efficient preventative effects in a cellular model of Parkinson's disease. J Cell Mol Med (2010) 0.89
Oxidative Stress in Neurodegenerative Diseases. Mol Neurobiol (2015) 0.89
Potential future neuroprotective therapies for neurodegenerative disorders and stroke. Clin Geriatr Med (2010) 0.88
Protection against Parkinson's disease progression: clinical experience. Neurotherapeutics (2008) 0.88
Coenzyme Q10 decreases amyloid pathology and improves behavior in a transgenic mouse model of Alzheimer's disease. J Alzheimers Dis (2011) 0.88
New aspects of mitochondrial Uncoupling Proteins (UCPs) and their roles in tumorigenesis. Int J Mol Sci (2011) 0.87
Serum cholesterol and the progression of Parkinson's disease: results from DATATOP. PLoS One (2011) 0.86
Design and implementation of the first randomized controlled trial of coenzyme CoQ₁₀ in children with primary mitochondrial diseases. Mitochondrion (2012) 0.86
Mitochondrial dysfunction in Parkinson's disease: pathogenesis and neuroprotection. Parkinsons Dis (2010) 0.86
Present and future drug treatment for Parkinson's disease. J Neurol Neurosurg Psychiatry (2005) 0.86
A randomized, double-blind, placebo-controlled study of oral coenzyme Q10 to relieve self-reported treatment-related fatigue in newly diagnosed patients with breast cancer. J Support Oncol (2013) 0.85
Parkinson's disease: oxidative stress and therapeutic approaches. Neurol Sci (2010) 0.85
Targeting the redox balance in inflammatory skin conditions. Int J Mol Sci (2013) 0.84
Coenzyme Q10 effects on creatine kinase activity and mood in geriatric bipolar depression. J Geriatr Psychiatry Neurol (2012) 0.83
Coenzyme Q10 deficiency in patients with Parkinson's disease. J Neurol Sci (2012) 0.83
Mitochondrial Medicine and the Neurodegenerative Mitochondriopathies. Pharmaceuticals (Basel) (2009) 0.83
Endogenous neuroprotection in chronic neurodegenerative disorders: with particular regard to the kynurenines. J Cell Mol Med (2011) 0.83
Nanomicellar formulation of coenzyme Q10 (Ubisol-Q10) effectively blocks ongoing neurodegeneration in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model: potential use as an adjuvant treatment in Parkinson's disease. Neurobiol Aging (2014) 0.82
Targeting the progression of Parkinson's disease. Curr Neuropharmacol (2009) 0.82
Trends in the molecular pathogenesis and clinical therapeutics of common neurodegenerative disorders. Int J Mol Sci (2009) 0.82
Molecular Advances Leading to Treatment Implications for Fragile X Premutation Carriers. Brain Disord Ther (2014) 0.81
The effect of coenzyme Q10 therapy in Parkinson disease could be symptomatic. Arch Neurol (2003) 0.81
The regulation of coenzyme q biosynthesis in eukaryotic cells: all that yeast can tell us. Mol Syndromol (2014) 0.81
Neuroprotection and antioxidants. Neural Regen Res (2016) 0.80
Complementary & alternative management of Parkinson's disease: an evidence-based review of eastern influenced practices. J Mov Disord (2014) 0.80
Neuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent Perspectives. Int J Mol Sci (2016) 0.80
Recent advances on the neuroprotective potential of antioxidants in experimental models of Parkinson's disease. Int J Mol Sci (2012) 0.80
Ubiquinol (reduced Coenzyme Q10) in patients with severe sepsis or septic shock: a randomized, double-blind, placebo-controlled, pilot trial. Crit Care (2015) 0.80
Novel therapeutic strategies in Parkinson's disease. Eur J Clin Pharmacol (2009) 0.79
Is Modulation of Oxidative Stress an Answer? The State of the Art of Redox Therapeutic Actions in Neurodegenerative Diseases. Oxid Med Cell Longev (2015) 0.79
Lipid dysfunction and pathogenesis of multiple system atrophy. Acta Neuropathol Commun (2014) 0.79
Biochemical diagnosis of coenzyme q10 deficiency. Mol Syndromol (2014) 0.79
Mitochondrial therapy for Parkinson disease. Arch Neurol (2002) 0.78
Current experience in testing mitochondrial nutrients in disorders featuring oxidative stress and mitochondrial dysfunction: rational design of chemoprevention trials. Int J Mol Sci (2014) 0.78
From small things. BMJ (2007) 0.77
Oral repeated-dose toxicity studies of coenzyme Q10 in beagle dogs. Int J Toxicol (2012) 0.77
Plasma 8-hydroxy-2'-deoxyguanosine Levels in Huntington Disease and Healthy Controls Treated with Coenzyme Q10. J Huntingtons Dis (2012) 0.77
Medical management of Parkinson's disease: focus on neuroprotection. Curr Neuropharmacol (2011) 0.77
Slowing the decline. Nature (2010) 0.76
Protective Effects of Coenzyme Q10 Against Hydrogen Peroxide-Induced Oxidative Stress in PC12 Cell: The Role of Nrf2 and Antioxidant Enzymes. Cell Mol Neurobiol (2015) 0.76
Nutraceuticals in Parkinson's Disease. Neuromolecular Med (2016) 0.76
Coenzyme Q10 protects hair cells against aminoglycoside. PLoS One (2014) 0.76
Orthomolecular medicine: the therapeutic use of dietary supplements for anti-aging. Clin Interv Aging (2006) 0.76
Oral administration of coenzyme Q₁₀ reduces MPTP-induced loss of dopaminergic nerve terminals in the striatum in mice. Neurol Sci (2011) 0.76
Coenzyme Q10 in early Parkinson disease. Arch Neurol (2003) 0.75
Mitochondrial therapy for Parkinson's disease: neuroprotective pharmaconutrition may be disease-modifying. Clin Pharmacol (2010) 0.75
Efficient GSH delivery using PAMAM-GSH into MPP-induced PC12 cellular model for Parkinson's disease. Regen Biomater (2016) 0.75
Platelet mitochondrial activity and pesticide exposure in early Parkinson's disease. Mov Disord (2015) 0.75
Coenzyme Q10 and Neurological Diseases. Pharmaceuticals (Basel) (2009) 0.75
Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature (2006) 15.69
Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA (2009) 8.40
Sequence variants in SLITRK1 are associated with Tourette's syndrome. Science (2005) 8.20
Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature (2011) 7.90
Functional engraftment of human ES cell-derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes. Nat Med (2006) 7.21
Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med (2014) 6.67
Reduced-median-network analysis of complete mitochondrial DNA coding-region sequences for the major African, Asian, and European haplogroups. Am J Hum Genet (2002) 6.02
Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin. Proc Natl Acad Sci U S A (2006) 5.78
Levodopa and the progression of Parkinson's disease. N Engl J Med (2004) 5.44
Early surgical therapy for drug-resistant temporal lobe epilepsy: a randomized trial. JAMA (2012) 5.40
Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. N Engl J Med (2010) 5.27
Pink1 regulates mitochondrial dynamics through interaction with the fission/fusion machinery. Proc Natl Acad Sci U S A (2008) 4.97
Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nat Genet (2010) 4.47
Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging (2009) 4.36
HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol (2002) 4.20
A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med (2013) 4.11
Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group. JAMA (2000) 4.10
Parkinson's disease. Hum Mol Genet (2007) 3.84
Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol (2010) 3.84
Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proc Natl Acad Sci U S A (2004) 3.73
Preparing for preventive clinical trials: the Predict-HD study. Arch Neurol (2006) 3.57
Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA (2002) 3.46
Randomized trial of deep brain stimulation for Parkinson disease: thirty-six-month outcomes. Neurology (2012) 3.46
Neural subtype specification of fertilization and nuclear transfer embryonic stem cells and application in parkinsonian mice. Nat Biotechnol (2003) 3.43
Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. Am J Hum Genet (2003) 3.39
Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat Clin Pract Neurol (2008) 3.35
Exaggerated inflammation, impaired host defense, and neuropathology in progranulin-deficient mice. J Exp Med (2009) 3.32
Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am J Hum Genet (2005) 3.29
Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat Neurosci (2009) 3.24
Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am J Pathol (2002) 3.23
Effect of deprenyl on the progression of disability in early Parkinson's disease. The Parkinson Study Group. N Engl J Med (1989) 2.97
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol (2003) 2.93
Age at onset in two common neurodegenerative diseases is genetically controlled. Am J Hum Genet (2002) 2.90
Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. The Parkinson Study Group. N Engl J Med (1999) 2.88
A pilot study of focused ultrasound thalamotomy for essential tremor. N Engl J Med (2013) 2.82
Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstet Gynecol (2003) 2.81
Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron (2003) 2.80
Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol (2008) 2.79
Alzheimer's brains harbor somatic mtDNA control-region mutations that suppress mitochondrial transcription and replication. Proc Natl Acad Sci U S A (2004) 2.77
Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. Trends Mol Med (2008) 2.74
Mutated human SOD1 causes dysfunction of oxidative phosphorylation in mitochondria of transgenic mice. J Biol Chem (2002) 2.68
Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol (2010) 2.67
Radiofrequency ablation of frequent, idiopathic premature ventricular complexes: comparison with a control group without intervention. Heart Rhythm (2007) 2.65
Inactivation of Drosophila DJ-1 leads to impairments of oxidative stress response and phosphatidylinositol 3-kinase/Akt signaling. Proc Natl Acad Sci U S A (2005) 2.58
Mitochondrial alpha-ketoglutarate dehydrogenase complex generates reactive oxygen species. J Neurosci (2004) 2.57
Resting state functional connectivity of the striatum in Parkinson's disease. Brain (2012) 2.53
Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol (2009) 2.46
Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS. Neurology (2013) 2.45
Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. J Biol Chem (2004) 2.43
A focus on the synapse for neuroprotection in Alzheimer disease and other dementias. Neurology (2004) 2.35
A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol (2004) 2.34
Genome-wide gene-environment study identifies glutamate receptor gene GRIN2A as a Parkinson's disease modifier gene via interaction with coffee. PLoS Genet (2011) 2.28
What is the risk of sham surgery in Parkinson disease clinical trials? A review of published reports. Neurology (2005) 2.25
Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease. Mov Disord (2012) 2.18
Beyond disgust: impaired recognition of negative emotions prior to diagnosis in Huntington's disease. Brain (2007) 2.17
Strategies to advance translational research into brain barriers. Lancet Neurol (2008) 2.16
The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study. BMC Med (2008) 2.10
Somatic mitochondrial DNA mutations in early Parkinson and incidental Lewy body disease. Ann Neurol (2012) 2.08
Lipid peroxidation in aging brain and Alzheimer's disease. Free Radic Biol Med (2002) 2.08
The human immune response to streptococcal extracellular antigens: clinical, diagnostic, and potential pathogenetic implications. Clin Infect Dis (2010) 2.04
The impact of litigation on neurologic research. Neurology (2006) 2.03
Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol (2004) 2.02
Sensitivity to oxidative stress in DJ-1-deficient dopamine neurons: an ES- derived cell model of primary Parkinsonism. PLoS Biol (2004) 2.02
Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J Neurosci (2002) 2.01
Parkin mutations and susceptibility alleles in late-onset Parkinson's disease. Ann Neurol (2003) 2.01
A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster. Pain (2009) 2.01
Testing objective measures of motor impairment in early Parkinson's disease: Feasibility study of an at-home testing device. Mov Disord (2009) 2.00
Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis (2006) 2.00
Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease. Hum Mol Genet (2003) 1.98
Mitochondrial dysfunction and amyotrophic lateral sclerosis. Muscle Nerve (2006) 1.95
TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol (2006) 1.95
Influence of heterozygosity for parkin mutation on onset age in familial Parkinson disease: the GenePD study. Arch Neurol (2006) 1.94
An evaluation of neurocognitive status and markers of immune activation as predictors of time to death in advanced HIV infection. Arch Neurol (2007) 1.94
Freezing of gait in PD: prospective assessment in the DATATOP cohort. Neurology (2001) 1.94
Head injury and Parkinson's disease risk in twins. Ann Neurol (2006) 1.93
Genome screen to identify susceptibility genes for Parkinson disease in a sample without parkin mutations. Am J Hum Genet (2002) 1.93
Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. PLoS One (2011) 1.93